The occurrence of psoriatic arthritis in Denmark

Pedersen, Ole Birger; Svendsen, Anders Jørgen; Ejstrup, Leif; Skytthe, Axel; Junker, Peter

doi:10.1136/ard.2007.082172

Cited by 40 publications

(22 citation statements)

References 38 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The true prevalence of PsA in the general population is not fully clear, but is reported to be 0.13-0.25% in the Nordic countries (2)(3)(4)(5). By applying classification criteria for psoriatic arthritis [ClASsification criteria for Psoriatic ARthritis (CASPAR) study] (6), the prevalence of PsA in psoriasis patients was estimated to be 13.8% (1), while other studies report a higher prevalence of 27-30% (7)(8)(9).…”

mentioning

confidence: 99%

Disease activity in and quality of life of patients with psoriatic arthritis mutilans: the Nordic PAM Study

Lindqvist

Guðbjörnsson

Iversen

et al. 2017

Scandinavian Journal of Rheumatology

Self Cite

View full text Add to dashboard Cite

Objective: To describe the social status and health-related quality of life of patients with psoriatic arthritis mutilans (PAM) in the Nordic countries. Method: Patients with at least one mutilated joint confirmed by radiology were studied. Disease activity involving joints and skin, physician-assessed disease activity, and patient's education and work status were recorded. Data from the 36-item Short Form Health Survey, Health Assessment Questionnaire and Dermatology Life Quality Index questionnaire were gathered and correlated with disease duration, pain, and general well-being (visual analogue scale). The controls were 58 Swedish patients with long-standing psoriatic arthritis sine PAM. Results: Sixty-seven patients were included. Patients with PAM had a protracted disease history (33 ± 14 years) and disease onset at a relatively early age (30 ± 12 years). Overall inflammatory activity at inclusion was mild to moderate. The mean number of mutilated joints was 8.2 and gross deformity was found in 16% of patients. Forty per cent were treated with biological and 32% with conventional synthetic disease-modifying anti-rheumatic drugs. Forty-two per cent had retired early or were on sick leave. Impaired functional capacity with little or no ability to perform self-care or everyday tasks was reported by 21% of the patients. Patients between 45 and 60 years of age reported the most impaired quality of life in comparison to the control group. Conclusion: PAM seriously affects social functioning. Whether early recognition of PAM and new forms of therapy can improve disease outcome and quality of life remains to be studied.

show abstract

mentioning

confidence: 99%

Disease activity in and quality of life of patients with psoriatic arthritis mutilans: the Nordic PAM Study

Lindqvist

Guðbjörnsson

Iversen

et al. 2017

Scandinavian Journal of Rheumatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Epidemiologische Daten zur PsA erscheinen in der Literatur sehr heterogen. So wird die Prävalenz einer PsA bei Patienten mit Psoriasis (Ps) zwischen 10% und 73% angegeben in Abhängigkeit von der Studienpopulation und den verwendeten zahlreichen Klassifikationskriterien [2,3,7,8,9].…”

Section: Originalien Hintergrund Und Fragestellungunclassified

GEPARD-Patientenfragebogen

Härle¹,

Hartung

Lehmann

et al. 2009

Z. Rheumatol.

View full text Add to dashboard Cite

show abstract

“…In a recent epidemiological study conducted in Denmark, the prevalence of PsA in the general population was estimated as 0.14% (95% confidence interval [CI]: 0.11%–0.19%) according to the Classification Criteria for Psoriatic Arthritis (CASPAR) [9]. In the United States, the overall age- and sex-adjusted annual incidence of PsA was 7.2 per 100,000 (95% CI: 6.0–8.4), with a higher incidence in men (9.1, 95% CI: 7.1–11.0) than in women (5.4, 95% CI: 4.0–6.9) [10].…”

Section: Incidence and Prevalence Of Psamentioning

confidence: 99%

The Diagnostic and Therapeutic Challenge of Early Psoriatic Arthritis

et al. 2010

View full text Add to dashboard Cite

Psoriasis is a complex disease involving the skin, nails and musculoskeletal structures. Psoriatic arthritis (PsA) affects peripheral joints, entheses, the synovial sheaths of tendons and the axial skeleton. PsA is now recognised as a potentially debilitating disease, with bone erosions and deformities affecting about half of patients and arising early after disease onset. Because PsA usually coincides with or follows the development of psoriasis, dermatologists are in a strategic position to diagnose and manage early PsA. In general, patients with severe psoriasis appear to have a higher risk of arthritis than patients with mild psoriasis. In addition, scalp lesions, nail dystrophy and intergluteal/perianal lesions have been found to be associated with a higher risk of PsA development. The diagnosis of PsA is based primarily on clinical features, and several classification criteria have been developed. Ultrasonography, magnetic resonance imaging and bone scintigraphy, rather than standard radiography, are the most accurate and effective diagnostic imaging approaches for documenting early PsA. The therapeutic strategy for early PsA should be aimed at inducing lasting remission, preventing permanent damage and possibly modifying the natural disease course.

show abstract

The occurrence of psoriatic arthritis in Denmark

Abstract: The positive predictive value of self-reported PsA was 31%. The prevalence and incidence figures of PsA were equivalent to the previously reported occurrence in population- and hospital-based studies.

Cited by 40 publications

References 38 publications

Disease activity in and quality of life of patients with psoriatic arthritis mutilans: the Nordic PAM Study

Disease activity in and quality of life of patients with psoriatic arthritis mutilans: the Nordic PAM Study

GEPARD-Patientenfragebogen

The Diagnostic and Therapeutic Challenge of Early Psoriatic Arthritis

Contact Info

Product

Resources

About